scholarly article | Q13442814 |
P356 | DOI | 10.1097/TP.0B013E3181726849 |
P698 | PubMed publication ID | 18580466 |
P2093 | author name string | Ulla Berg | |
Gunilla Kumlien | |||
Gunnar Tydén | |||
Helena Genberg | |||
Lars Wennberg | |||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | rituximab | Q412323 |
P304 | page(s) | 1745-1754 | |
P577 | publication date | 2008-06-01 | |
P1433 | published in | Transplantation | Q15730500 |
P1476 | title | ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up | |
P478 | volume | 85 |
Q38306136 | A systematic review of the use of rituximab as induction therapy in renal transplantation |
Q87273092 | AB0 incompatible kidney transplantation using unspecific immunoadsorption |
Q35607565 | ABO Incompatible Kidney Transplantation-Current Status and Uncertainties |
Q51762531 | ABO antibody and complement depletion by immunoadsorption combined with membrane filtration--a randomized, controlled, cross-over trial. |
Q37803412 | ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? |
Q28236829 | ABO incompatible renal transplants: Good or bad? |
Q90252745 | ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis |
Q36696495 | ABO-incompatible renal transplantation in developing world - crossing the immunological (and mental) barrier. |
Q35524699 | ABO-incompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier |
Q38325273 | Adsorption of chain type-specific ABO antibodies on Sepharose-linked A and B tetrasaccharides |
Q36066503 | Alternative Living Kidney Donation Programs Boost Genetically Unrelated Donation |
Q38267202 | An update on ABO-incompatible kidney transplantation |
Q37800331 | Antibody immunosuppressive therapy in solid organ transplant |
Q38286995 | Antibody-incompatible kidney transplantation in 2015 and beyond |
Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
Q42038591 | B-cell tolerance in transplantation: is repertoire remodeling the answer? |
Q34159016 | B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. |
Q37994745 | Beyond dialysis: current and emerging blood purification techniques. |
Q26829578 | Biologics in organ transplantation |
Q94661248 | Clinical Characteristic and Outcomes of BK Virus Infection in Kidney Transplant Recipients Managed Using a Systematic Surveillance and Treatment Strategy |
Q90047669 | Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis |
Q38445752 | Comparative analysis of ABO-incompatible living donor kidney transplantation with ABO-compatible grafts: a single-center experience in Korea |
Q37834028 | Current immunosuppressive treatment after kidney transplantation |
Q36171175 | Current progress in ABO-incompatible kidney transplantation |
Q98727034 | Current protocols and outcomes of ABO-incompatible kidney transplantation |
Q37547425 | Desensitization protocol enabling pediatric crossmatch-positive renal transplantation: successful HLA-antibody-incompatible renal transplantation of two highly sensitized children |
Q38001495 | Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe? |
Q38460398 | Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation |
Q40815282 | Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations |
Q38680131 | Discontinuation of steroids in ABO-incompatible renal transplantation. |
Q35543289 | Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients. |
Q51955356 | Effects of B cell depletion on T cell allogeneic immune responses: a strategy to reduce allogeneic sensitization. |
Q58999579 | Effects of Rituximab on the Development of Viral and Fungal Infections in Renal Transplant Recipients |
Q36400872 | Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation: Experience of one center |
Q37766166 | Immunogenicity and allogenicity: a challenge of stem cell therapy |
Q37830813 | Immunohaematological and apheretic aspects of the first kidney transplant from a living, ABO-incompatible donor carried out in Italy |
Q36126901 | Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients |
Q28741418 | Incompatible live-donor kidney transplantation in the United States: results of a national survey |
Q50987486 | Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study. |
Q35664634 | Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin |
Q35953320 | Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation |
Q38006827 | Innovative strategies in living donor kidney transplantation |
Q37776364 | Isoagglutinin adsorption in ABO-incompatible transplantation |
Q45972317 | Isoagglutinin titre adsorption: breaking the barrier in major AB0-incompatible organ transplantation. |
Q50177273 | Late Steroid Withdrawal Following AB0-Incompatible Renal Transplantation. |
Q100517385 | Long-term Follow-up of ABO-Incompatible Kidney Transplantation in Freiburg, Germany: A Single-Center Outcome Report |
Q38570443 | Long-term Outcomes of ABO-Incompatible Living Donor Kidney Transplantation: A Comparative Analysis |
Q34786113 | Mimotope selection of blood group A antigen from a phage display 15-mer peptide library |
Q27010224 | Modern approaches to incompatible kidney transplantation |
Q26826880 | Monoclonal antibody therapy and renal transplantation: focus on adverse effects |
Q37901973 | Neurological complications of transplantation |
Q40271255 | One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience |
Q35822937 | Outcomes of ABO-incompatible kidney transplantation in the United States |
Q91554083 | Percentage of CD19+ Cells in Peripheral Blood Lymphocytes After Rituximab-Based Desensitization as a Predictor of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation |
Q37369319 | Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. |
Q41527816 | Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. |
Q37989298 | Rituximab in immunologic glomerular diseases |
Q48511018 | Safety and Efficacy of Induction Therapy With Thymoglobulin in AB0-Incompatible Kidney Transplantation |
Q38468859 | Short-term results of ABO-incompatible living donor kidney transplantation: comparison with ABO-compatible grafts |
Q89029586 | Similar Microvascular Inflammation and Tubulointerstitial Injury in ABO-Incompatible and Matched ABO-Compatible Kidney Allografts |
Q39903845 | Specific issues in living donor kidney transplantation: ABO - incompatibility |
Q35022239 | Strategies to increase the donor pool and access to kidney transplantation: an international perspective |
Q40503602 | Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases |
Q37615262 | The First Fifty ABO Blood Group Incompatible Kidney Transplantations: The Rotterdam Experience |
Q38118112 | Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. |
Q84453096 | Transplantation: ABO-incompatible renal transplants: time for increased use? |
Q33396236 | Use of monoclonal antibodies in renal transplantation |
Q43982164 | Vienna experience of ABO-incompatible living-donor kidney transplantation |
Q84867357 | [Extending the donor pool in renal transplantation] |
Search more.